Our aim was to determine whether right ventricular (RV) dysfunction at 24-hour postnatal age predicts adverse developmental outcome among patients with hypoxic ischaemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH).
Neonates?35 weeks with HIE/TH were enrolled in a physiological study in the neonatal period (n=46) and either died or underwent neurodevelopmental follow-up at 18 months (n=43). The primary outcome was a composite of death, diagnosis of cerebral palsy or any component of the Bayley Scores of Infant Development III&lt;70. We hypothesised that tricuspid annulus plane systolic excursion (TAPSE) &lt;6 mm and/or RV fractional area change (RV-FAC) &lt;0.29 would predict adverse outcome.
Nine patients died and 34 patients were followed up at a mean age of 18.9±1.4 months. Both indices of RV systolic performance were abnormal in 15 (35%) patients, TAPSE &lt;6 mm only was abnormal in 4 (9%) patients and RV-FAC &lt;0.29 only was abnormal in 5 (12%) patients (19 had with normal RV function). Although similar at admission, neonates with RV dysfunction had higher cardiovascular and neurological illness severity by 24 hours than those without and severe MRI abnormalities (70% vs 53%, p=0.01) were more common. On logistic regression, TAPSE &lt;6 mm (OR 3.6, 95% CI 1.2 to 10.1; p=0.017) and abnormal brain MRI [OR 21.7, 95% CI 1.4 to 336; p=0.028) were independently associated with adverse outcome. TAPSE &lt;6 mm predicted outcome with a 91% sensitivity and 81% specificity.
The role of postnatal cardiovascular function on neurological outcomes among patients with HIE who receive TH merits further study. Quantitative measurement of RV function at 24 hours may provide an additional neurological prognostic tool.
The role of postnatal cardiovascular function on neurological outcomes among patients with HIE who receive TH merits further study. Quantitative measurement of RV function at 24 hours may provide an additional neurological prognostic tool.In response to a sharp rise in opioid-involved overdose deaths in the USA, states have deployed increasingly aggressive strategies to limit the loss of life, including civil commitment-the forcible detention of individuals whose opioid use presents a clear and convincing danger to themselves or others. While civil commitment often succeeds in providing short-term protection from overdose, emerging evidence suggests that it may be associated with long-term harms, including heightened risk of severe withdrawal, relapse and opioid-involved mortality. To better assess and mitigate these harms, states should collect more robust data on long-term health outcomes, decriminalise proceedings and stays, provide access to medications for opioid use disorder and strengthen post-release coordination of community-based treatment.A sonnet about transcortical sensory aphasia, a disorder in which comprehension remains intact, but language production is primarily constrained to repetition. https://www.selleckchem.com/products/Aminocaproic-acid(Amicar).html Much like the mythical Echo, this sonnet is a reflection upon personal expression when one's words are not one's own.To compare differences in healthcare resource utilization (HcRU) over time between Medicare beneficiaries with and without Parkinson's disease (PD).
This retrospective observational study utilized the Chronic Conditions Data Warehouse (5% Medicare sample) between 2005 and 2015. In a propensity-score matched (age, sex, race, and comorbidity adjusted) sample of beneficiaries with and without PD, we examined all-cause HcRU due to inpatient admissions, emergency department (ED) admissions, skilled nursing facility (SNF) admissions, healthcare provider encounters, neurologist visits, rehabilitation service visits, and non-PD medication fills. Relative to beneficiaries without PD, we reported adjusted incidence rate ratios (IRR) and 95% confidence intervals (CI) for beneficiaries with PD using generalized linear models (GLM) with log link and negative binomial variance functions.
A total of 467,064 Medicare enrollees (unmatched sample) met the inclusion criteria. Of these, 3.3% had PD. In the matched sample and relative to beneficiaries without PD, beneficiaries with PD displayed higher rates of inpatient admissions (IRR 1.29; 95% CI 1.24, 1.34), ED admissions (IRR 1.31; 95% CI 1.27, 1.34); SNF admissions (IRR 2.00; 95% CI 1.92, 2.09), healthcare provider encounters (IRR 1.18; 95% CI 1.16, 1.20), neurologist visits (IRR 5.57; 95% CI 5.35, 5.78), rehabilitation service visits (IRR 1.47; 95% CI 1.41, 1.53), and non-PD medication fills (IRR 1.10, 95% CI 1.08, 1.11) over time.
These results reflect patterns of medical care among Medicare beneficiaries with PD. The findings can help clinicians, payers, and policymakers make evidence-based decisions for the allocation of scarce healthcare resources for PD management.
This study provides Class II evidence that Medicare beneficiaries with PD use more health care resources than matched controls without PD.
This study provides Class II evidence that Medicare beneficiaries with PD use more health care resources than matched controls without PD.To explore safety and efficacy of artificial coma induction to treat status epilepticus (SE) immediately after first-line antiseizure treatment instead of following the recommended approach of first using second-line drugs.
Clinical and electrophysiologic data of all adult patients treated for SE from 2017 to 2018 in the Swiss academic medical care centers from Basel and Geneva were retrospectively assessed. Primary outcomes were return to premorbid neurologic function and in-hospital death. Secondary outcomes were the emergence of complications during SE, duration of SE, ICU and hospital stay.
Of 230 patients, 205 received treatment escalation after first-line medication. Of those, 27.3% were directly treated with artificial coma and 72.7% with second-line non-anesthetic antiseizure drugs. Of the latter, 16.6% were subsequently put on artificial coma after failure of second-line treatment. Multivariable analyses revealed increasing odds for coma induction after first-line treatment with younger age, the presence of convulsions, and with an increased SE severity as quantified by the Status Epilepticus Severity Score (STESS).